IESE (España)
-
Riverside: The Acquisition of Euromed : Investment Process of a Private Equity
Martínez Abascal, Eduardo; Sagarra, MartíCase F-962-EFinanceIn December 2015, Riverside PE (private equity) had to present a blind offer for the acquisition of Euromed, together with the financing of the operation. Euromed produces active ingredients for medical use. Euromed enjoys a profitable niche (good margins), with few competitors, high barriers and promising growth opportunities. It has sales of around 43 million euros, with 300 clients in 35 countries.Starting at €8.20
-
BioRecilGent (B)
Miguel A. Ariño; Rodríguez Mariscal, ManuelCase AD-381-EDecision AnalysisThe case focuses on the development of a yet-to-be-approved drug. It presents the various options open to the company developing the drug in the context of the phases that the medicine must go through to be approved.Starting at €5.74
-
BioRecilGent (A)
Miguel A. Ariño; Rodríguez Mariscal, ManuelCase AD-380Decision AnalysisEl caso presenta el desarrollo de un fármaco que todavía no está aprobado. Muestra las distintas opciones que tiene la empresa que lo desarrolla, según las diferentes fases para su aprobación.Starting at €8.20
-
Riverside: The Acquisition of Euromed : Investment Process of a Private Equity (Portuguese Version, Brazil)
Martínez Abascal, Eduardo; Sagarra, MartíCase F-962-PBFinanceIn December 2015, Riverside PE (private equity) had to present a blind offer for the acquisition of Euromed, together with the financing of the operation. Euromed produces active ingredients for medical use. Euromed enjoys a profitable niche (good margins), with few competitors, high barriers and promising growth opportunities. It has sales of around 43 million euros, with 300 clients in 35 countries. This case is an updated version of the case ...Starting at €8.20
-
Riverside: la compra de Euromed: Proceso inversor de una private equity
Martínez Abascal, Eduardo; Sagarra, MartíCase F-962FinanceEn diciembre de 2015 Riverside PE (private equity), tiene que presentar una oferta ciega para la adquisición de Euromed, junto con la financiación de la operación. Euromed produce ingredientes activos para uso médico. Euromed disfruta de un buen nicho rentable (buenos márgenes), con pocos competidores, altas barreras y prometedoras oportunidades de crecimiento. Ventas alrededor de 43 millones de euros, con 300 clientes en 35 países.Starting at €8.20
-
BioRecilGent (B)
Miguel A. Ariño; Rodríguez Mariscal, ManuelCase AD-381Decision AnalysisEl caso presenta el desarrollo de un fármaco que todavía no está aprobado. Muestra las distintas opciones que tiene la empresa que lo desarrolla, según las diferentes fases para su aprobación.Starting at €5.74
-
BioRecilGent (A)
Miguel A. Ariño; Rodríguez Mariscal, ManuelCase AD-380-EDecision AnalysisThe case focuses on the development of a yet-to-be-approved drug. It presents the various options open to the company developing the drug in the context of the phases that the medicine must go through to be approved.Starting at €8.20
-
Riverside: The Acquisition of Euromed : Investment Process of a Private Equity (Portuguese version, Portugal)
Martínez Abascal, Eduardo; Sagarra, MartíCase F-962-PPFinanceIn December 2015, Riverside PE (private equity) had to present a blind offer for the acquisition of Euromed, together with the financing of the operation. Euromed produces active ingredients for medical use. Euromed enjoys a profitable niche (good margins), with few competitors, high barriers and promising growth opportunities. It has sales of around 43 million euros, with 300 clients in 35 countries.Starting at €8.20